Jared A. Gollob
Net Worth

Last updated:

What is Jared A. Gollob net worth?

The estimated net worth of Dr. Jared A. Gollob is at least $16,456,280 as of 16 Jul 2024. He owns shares worth $4,064,158 as insider, has earned $10,083,282 from insider trading and has received compensation worth at least $2,308,840 in Kymera Therapeutics, Inc..

What is the salary of Jared A. Gollob?

Dr. Jared A. Gollob salary is $577,210 per year as Chief Medical Officer in Kymera Therapeutics, Inc..

How old is Jared A. Gollob?

Dr. Jared A. Gollob is 61 years old, born in 1964.

What stocks does Jared A. Gollob currently own?

As insider, Dr. Jared A. Gollob owns shares in one company:

Company Title Shares Price per share Total value
Kymera Therapeutics, Inc. (KYMR) Chief Medical Officer 95,470 $42.57 $4,064,158

What does Kymera Therapeutics, Inc. do?

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR logo
KYMR
Kymera Therapeutics, Inc.
$42.57

Jared A. Gollob insider trading

Kymera Therapeutics, Inc.

Dr. Jared A. Gollob has made 21 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 46,137 units of KYMR stock on 9 Feb 2024. As of 16 Jul 2024 he still owns at least 95,470 units of KYMR stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 23,145 $2.08 $48,142
Option
Common Stock 23,145 $2.08 $48,142
Sale
Common Stock 9,864 $46.1 $454,701
Sale
Common Stock 13,281 $45.59 $605,521
Sale
Common Stock 16,455 $45.15 $742,927
Option
Stock Option (Right to Buy) 16,455 $2.08 $34,226
Option
Common Stock 16,455 $2.08 $34,226
Sale
Common Stock 2,022 $41.41 $83,739
Sale
Common Stock 216 $43.26 $9,343
Sale
Common Stock 1,106 $42.39 $46,886
Sale
Common Stock 400 $45 $18,000
Option
Stock Option (Right to Buy) 400 $2.08 $832
Option
Common Stock 400 $2.08 $832
Option
Stock Option (Right to Buy) 46,137 $2.08 $95,965
Sale
Common Stock 7,398 $36.09 $267,016
Option
Common Stock 46,137 $2.08 $95,965
Sale
Common Stock 38,739 $35.39 $1,371,051
Sale
Common Stock 297 $31.4 $9,325
Sale
Common Stock 1,001 $30.88 $30,908
Option
Common Stock 10,208 $1.31 $13,372
Option
Common Stock 9,792 $2.08 $20,367
Option
Stock Option (Right to Buy) 9,792 $2.08 $20,367
Option
Stock Option (Right to Buy) 10,208 $1.31 $13,372
Option
Stock Option (Right to Buy) 39,603 $1.82 $72,196
Sale
Common Stock 14,996 $63.58 $953,386
Option
Common Stock 14,996 $2.08 $31,192
Sale
Common Stock 42,497 $61.85 $2,628,524
Option
Common Stock 24,607 $1.7 $41,709
Sale
Common Stock 10,305 $60.17 $620,052
Option
Common Stock 7,800 $1.31 $10,218
Option
Stock Option (Right to Buy) 7,800 $1.31 $10,218
Option
Common Stock 2,200 N/A N/A
Option
Stock Option (Right to Buy) 2,200 N/A N/A
Sale
Common Stock 4,695 N/A N/A
Sale
Common Stock 8,675 $50.91 $441,670
Sale
Common Stock 19,285 $49.65 $957,558
Sale
Common Stock 9,104 $52.63 $479,134
Sale
Common Stock 8,887 N/A N/A
Sale
Common Stock 6,499 $55.94 $363,541
Sale
Common Stock 7,550 N/A N/A

Kymera Therapeutics key executives

Kymera Therapeutics, Inc. executives and other stock owners filed with the SEC: